Literature DB >> 19352411

SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.

Claire Beneteau1, Hélène Cavé, Anne Moncla, Nathalie Dorison, Arnold Munnich, Alain Verloes, Bruno Leheup.   

Abstract

We report five cases of multiple giant cell lesions in patients with typical Noonan syndrome. Such association has frequently been referred to as Noonan-like/multiple giant cell (NL/MGCL) syndrome before the molecular definition of Noonan syndrome. Two patients show mutations in PTPN11 (p.Tyr62Asp and p.Asn308Asp) and three in SOS1 (p.Arg552Ser and p.Arg552Thr). The latter are the first SOS1 mutations reported outside PTPN11 in NL/MGCL syndrome. MGCL lesions were observed in jaws ('cherubism') and joints ('pigmented villonodular synovitis'). We show through those patients that both types of MGCL are not PTPN11-specific, but rather represent a low penetrant (or perhaps overlooked) complication of the dysregulated RAS/MAPK signaling pathway. We recommend discarding NL/MGCL syndrome from the nosology, as this presentation is neither gene-nor allele-specific of Noonan syndrome; these patients should be described as Noonan syndrome with MGCL (of the mandible, the long bone...). The term cherubism should be used only when multiple giant cell lesions occur without any other clinical and molecular evidence of Noonan syndrome, with or without mutations of the SH3BP2 gene.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19352411      PMCID: PMC2986637          DOI: 10.1038/ejhg.2009.44

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  40 in total

1.  Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism.

Authors:  Y Ueki; V Tiziani; C Santanna; N Fukai; C Maulik; J Garfinkle; C Ninomiya; C doAmaral; H Peters; M Habal; L Rhee-Morris; J B Doss; S Kreiborg; B R Olsen; E Reichenberger
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

2.  Are Noonan syndrome and Noonan-like/multiple giant cell lesion syndrome distinct entities?

Authors:  D R Bertola; C A Kim; A C Pereira; G F Mota; J E Krieger; I C Vieira; M Valente; M R Loreto; R P Magalhães; C H Gonzalez
Journal:  Am J Med Genet       Date:  2001-01-22

3.  The Noonan syndrome/cherubism association.

Authors:  C Dunlap; B Neville; R A Vickers; D O'Neil; B Barker
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1989-06

4.  Short stature in Noonan syndrome: response to growth hormone therapy.

Authors:  J M Kirk; P R Betts; G E Butler; M D Donaldson; D B Dunger; D I Johnston; C J Kelnar; D A Price; P Wilton
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

5.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.

Authors:  Marco Tartaglia; Kamini Kalidas; Adam Shaw; Xiaoling Song; Dan L Musat; Ineke van der Burgt; Han G Brunner; Débora R Bertola; Andrew Crosby; Andra Ion; Raju S Kucherlapati; Steve Jeffery; Michael A Patton; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2002-05-01       Impact factor: 11.025

6.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

Authors:  M Tartaglia; E L Mehler; R Goldberg; G Zampino; H G Brunner; H Kremer; I van der Burgt; A H Crosby; A Ion; S Jeffery; K Kalidas; M A Patton; R S Kucherlapati; B D Gelb
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

7.  A case of neurofibromatosis-Noonan syndrome with a central giant cell granuloma.

Authors:  Maryam Yazdizadeh; Jose Luis Tapia; Maryam Baharvand; Lida Radfar
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

8.  PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.

Authors:  M Maheshwari; J Belmont; S Fernbach; T Ho; L Molinari; I Yakub; F Yu; A Combes; J Towbin; W J Craigen; R Gibbs
Journal:  Hum Mutat       Date:  2002-10       Impact factor: 4.878

9.  Polyarticular pigmented villonodular synovitis in children: evidence for a genetic contribution.

Authors:  R G Wendt; F Wolfe; D McQueen; P Murphy; H Solomon; M Housholder
Journal:  J Rheumatol       Date:  1986-10       Impact factor: 4.666

10.  Neurofibromatosis 1: a novel NF1 mutation in an 11-year-old girl with a giant cell granuloma.

Authors:  Uta Krammer; Katharina Wimmer; Peter Wiesbauer; Michael Rasse; Susanna Lang; Andrea Müllner-Eidenböck; Herwig Frisch
Journal:  J Child Neurol       Date:  2003-05       Impact factor: 1.987

View more
  18 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  Cherubism.

Authors:  Nurgül Kömerik; Betül Taş; Levent Önal
Journal:  Head Neck Pathol       Date:  2013-09-14

3.  Giant cell lesion of the jaw as a presenting feature of Noonan syndrome.

Authors:  Bridget P Sinnott; Maya Patel
Journal:  BMJ Case Rep       Date:  2018-05-30

4.  Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.

Authors:  Hélène Cavé; Aurélie Caye; Nehla Ghedira; Yline Capri; Nathalie Pouvreau; Natacha Fillot; Aurélien Trimouille; Cédric Vignal; Odile Fenneteau; Yves Alembik; Jean-Luc Alessandri; Patricia Blanchet; Odile Boute; Patrice Bouvagnet; Albert David; Anne Dieux Coeslier; Bérénice Doray; Olivier Dulac; Valérie Drouin-Garraud; Marion Gérard; Delphine Héron; Bertrand Isidor; Didier Lacombe; Stanislas Lyonnet; Laurence Perrin; Marlène Rio; Joëlle Roume; Sylvie Sauvion; Annick Toutain; Catherine Vincent-Delorme; Marjorie Willems; Clarisse Baumann; Alain Verloes
Journal:  Eur J Hum Genet       Date:  2016-01-13       Impact factor: 4.246

5.  Multifocal tenosynovial giant cell tumors in a child with Noonan syndrome.

Authors:  Arthur B Meyers; Agboola O Awomolo; Sara Szabo
Journal:  Pediatr Radiol       Date:  2016-11-23

Review 6.  Benefits of molecular pathology in the diagnosis of musculoskeletal disease : Part II of a two-part review: bone tumors and metabolic disorders.

Authors:  Adrienne M Flanagan; David Delaney; Paul O'Donnell
Journal:  Skeletal Radiol       Date:  2009-08-11       Impact factor: 2.199

7.  Neurofibromatosis Type 1 With Cherubism-like Phenotype, Multiple Osteolytic Bone Lesions of Lower Extremities, and Alagille-syndrome: Case Report With Literature Survey.

Authors:  Reinhard E Friedrich; Jozef Zustin; Andreas M Luebke; Thorsten Rosenbaum; Martin Gosau; Christian Hagel; Felix K Kohlrusch; Ilse Wieland; Martin Zenker
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

Review 8.  Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Ann N Y Acad Sci       Date:  2010-10-19       Impact factor: 5.691

9.  NGS testing for cardiomyopathy: Utility of adding RASopathy-associated genes.

Authors:  Ozge Ceyhan-Birsoy; Maya M Miatkowski; Elizabeth Hynes; Birgit H Funke; Heather Mason-Suares
Journal:  Hum Mutat       Date:  2018-05-16       Impact factor: 4.878

10.  A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.

Authors:  Raphael Carapito; Nicodème Paul; Meiggie Untrau; Louise Ott; Nadège Corradini; Sylvaine Poignant; Loïc Geffroy; Emmanuelle Caldagues; Marie-Françoise Heymann; Elisabeth Cassagnau; Bertrand Isidor; Seiamak Bahram
Journal:  J Hum Genet       Date:  2013-11-14       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.